Israel’s DreaMed (see here previously) has now received US FDA approval for use with Type 2 diabetes sufferers as well as Type 1. It will relieve the strain on endocrinologist who each have on average some 46,000 patients. https://www.timesofisrael.com/spotlight/israeli-startup-offers-hope-in-global-diabetes-crisis/

Israel’s DreaMed Diabetes (see here) has partnered a number of US health clinics. Lucile Packard Children’s Hospital Stanford; Billings Clinic Montana; Hassenfeld Children’s Hospital, NYU Langone and UF Health will provide diabetes patients with DreaMed’s personalized solutions. https://www.businesswire.com/news/home/20200930005419/en/DreaMed-Expands-Its-Remote-Diabetes-Solution-to-Four-Clinics-Across-The-U.S.

Israel’s DreaMed Diabetes (reported here previously) is integrating its Advisor Pro software at Texas Children’s Hospital. It allows diabetic children to be monitored remotely and avoids the risk of them (and their parents / guardians) being infected in hospital with … Continue reading →

I’ve reported previously (see here) on the diabetes monitors from Israel’s DreaMed. The US FDA has just given approval to DreaMed’s Advisor Pro, to add to its EU approval. The software tells Type 1 diabetics how much insulin to use, … Continue reading →

I reported previously (see here) on Israel’s DreaMed Diabetes monitors. DreaMed has just partnered with French company BioCorp to create an Artificially Intelligent system that integrates BioCorp’s Mallya smart cap for pen injectors with DreaMed’s Advisor Pro insulin analysis system. … Continue reading →

I reported previously (10th Mar) that Israel’s DreaMed received European approval for its Advisor Pro diabetes monitor. Now the US FDA has given its approval. Advisor Pro provides insulin delivery recommendations by analyzing information from diabetes pumps and glucose monitoring. … Continue reading →

Israeli medical tech firm DreaMed Diabetes has struck a deal with Medtronic, the world’s biggest medical device company, to use its MD-Logic Artificial Pancreas algorithm in Medtronic’s insulin pumps. The algorithm regulates the insulin released to the diabetic individual. http://www.timesofisrael.com/diabetics-worldwide-to-benefit-from-artificial-pancreas/

I reported previously (twice) about Israel’s DreaMed Diabetes monitors for analyzing the data from Continuous Glucose Monitors (CGMs). DreaMed has just received the CE mark from the European Union for its Advisor Pro product. https://www.timesofisrael.com/israeli-smart-software-harnesses-flood-of-data-to-manage-diabetes-care/ https://www.youtube.com/embed/_eMkeq0lrFc?rel=0

Israel’s DreaMed Diabetes is developing a decision support technology platform called the Advisor to determine optimal patient-specific insulin treatment plans leading to balanced glucose levels in people with diabetes.  DreaMed has just raised $3.3 million for development. http://www.prnewswire.com/news-releases/dreamed-diabetes-raises-33-million-from-norma-investments-and-a-strategic-investor-300303138.html